With the weak economy, drug makers have been scaling back their drug development plans. The slowdown has trickled down to the so-called contract research organizations (CRO), which help pharmaceutical and biotechnology firms manage the necessary clinical trials for a drug to be licensed and marketed.
Many CRO's have tumbled, with short-term bearish sentiment hanging like a cloud over the group.
As the chart below shows, CVD traded as high as $58.95 in mid-September. On Wednesday, December 9th, it hit a low of $50.05.
The $50 level is significant in a number of ways. First, notice that CVD found resistance at $50 between June and August. Since old resistance should be new support, technical analysis theory says the shares should find buying balance sheet at this level. Of course, $50 is a round number, and stocks often find what I call round-number resistance and support at these levels.
As I write this at about 11:00 A.M. Eastern Time, the stock is up about $0.50 and is probing $51. It appears that buying interest has emerged at $50. Daily stochastics is at 33 and is at its most oversold level since March, when CVD bottomed along with the S&P 500.
There is some resistance at about $52, the previous support between September and December. Given the strong fundamentals, I believe this resistance will be penetrated. I am setting a target of $56.95. My stop loss is $47.35, just below the rising 200-day moving average.
If the stock hits my target, the gain will be in the order of +11.7%. If the stop loss is touched, the loss will be about -7.2%. That is a risk/reward ratio of 1.63 to 1.
In the interest of disclosure, on Wednesday, I took a small call option position in the January 50s. I bought my calls when CVD held $50 and had a weak bounce.
Action to Take: